Search
for

    Sort by

    Community Join

    990-1000 / 1000+ results

      community Anyone tried Thicair? thoughts?

      in Product 10 months ago
      Thicair is a product combining microneedling and subdural vitamins for hair loss, containing ingredients like Panax Ginseng Root Extract and Copper Tripeptide-1. Users are skeptical, with one calling it "quackery."

      community Where the fuck are the pyrilutamide GB guys?

      in Chat  23 upvotes 4 years ago
      The effects of Pyrilutamide, a hair loss treatment that is being tested for June/July; and reports from people who have experienced side effects similar to those of RU58841, suggesting they may have been sold an incorrect product from their supplier.

      community Chinese Research Chemicals You Suggest

      in Research/Science  3 upvotes 10 months ago
      The conversation discusses hair loss treatments, specifically RU58841, with mentions of side effects from finasteride and dutasteride. Alternatives like Pyri, KX-826, and Breezula are also mentioned.

      community KX-826 Phase 3 Failed. Sorry guys...

      in Research/Science  48 upvotes 2 years ago
      The conversation discusses the failure of Phase 3 trials for the hair loss treatment KX-826, with no significant difference found between the drug and placebo. Some users express disappointment and skepticism, while others discuss alternative treatments like Minoxidil, finasteride, and RU58841.

      community Thoughts on a previous stack m

      in Product  4 upvotes 1 year ago
      The conversation discusses past and current hair loss treatments, with the user reflecting on expensive peptide treatments like topical Dutasteride, Latanoprost, and others, which were ultimately deemed less effective than oral Dutasteride and Minoxidil. The user now prefers the latter due to their cost-effectiveness and efficacy.

      community GT20029 - Promising phase II results

      in Research/Science  15 upvotes 2 years ago
      GT20029 showed significant hair growth and safety in phase II trials, with no adverse sexual events. Users are hopeful but concerned about future costs and systemic effects.